JonesPBBarnesTRDaviesL. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry2006; 63: 1079–1087.
2.
LewisSWBarnesTRDaviesL. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull2006; 32: 715–723.
3.
SchulzCTimmJCordesJ. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clin Trials2016; 13: 251–259.
4.
DunnG. Commentary on Schulz et al.Clin Trials2016; 13; 260–261.
5.
LiebermanJAStroupTSMcEvoyJP.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med2005; 353: 1209–1223.
6.
StroupTSLiebermanJAMcEvoyJP. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry2007; 164: 415–427.
7.
KahnRSFleischhackerWWBoterH., EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet2008; 371: 1085–1097.
8.
RosenheckRAKrystalJHLewR. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials2011; 8: 196–204.
9.
McPhersonKBrittonARWennbergJE.Are randomized controlled trials controlled? Patient preferences and unblind trials. J R Soc Med1997; 90: 652–656.
